• CalciMedica is trading at $0.96 (up 6.2%) in pre-market action following news of a shift in top management.
  • The company announced on July 8, 2026, an increase in its board size to eight directors and the appointment of Evgeny Zaytsev as a new director, with Fred Middleton retiring.
  • This news follows a sharp decline triggered by the discontinuation of the Auxora acute kidney injury trial on January 28, 2026, due to safety concerns.